WO2005040147A1 - 抗腫瘍剤 - Google Patents
抗腫瘍剤 Download PDFInfo
- Publication number
- WO2005040147A1 WO2005040147A1 PCT/JP2004/016354 JP2004016354W WO2005040147A1 WO 2005040147 A1 WO2005040147 A1 WO 2005040147A1 JP 2004016354 W JP2004016354 W JP 2004016354W WO 2005040147 A1 WO2005040147 A1 WO 2005040147A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- ascopilone
- cell
- anhydrofructose
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
Definitions
- the present invention relates to an antitumor agent comprising 1,5-D-anhydrofructose and ⁇ or ascopilone as active ingredients.
- 1,5-D-Fanhydrofructose is a sugar having a specific structure in which one water molecule is removed from glucose. It has already been reported that it has antioxidant activity (see Japanese Patent Application Laid-Open No. Hei 9-1505988) and antibacterial activity (see Japanese Patent Application No. 2001-89377). In addition, recent studies have reported that it has a hyperglycemic inhibitory effect (see Japanese Patent Publication No. 2003-519660), and it is also attracting attention as a novel physiologically active sugar.
- ascopirone can be prepared from 1,5-D-anhydrofructose by an enzymatic reaction (see WO 3Z38084, WO 03/38085 and WOO 3Z38107).
- Ascopirone was originally known to be biosynthesized by certain ascomycetes (see MA Baute, phy tochemi stry, 33, (1991) 41-45).
- Ascopirone P (2_Hyd roxyme t hy l— 5—hyd r oxy— 2,3-di hyd r o-4H-pyr an-4-one) was obtained in 1978 and 1 Prepared in 981 by a group of scientists in the United States for the purpose of using ascopilone P as a starting material for organic synthesis by pyrolyzing amyctic pectin, amylose, and cellulose (Sha jazz ad eh). , F., eta 1., Carbohyd r. Res., 67, (1978) 433-447 and Stevenson, F., eta1., Carbohyd r. Res., 90, (1981 319-325).
- Ascopilone P (hereinafter sometimes abbreviated as APP) has been reported to have antioxidant and antibacterial activities similar to 1,5-D-anhydrofructose (WO02 / 26060, WO02 / 26061 and lAVOO). 0/56838). Many of the antitumor agents currently used in clinical settings have a pro-oxidant effect due to their chemical properties, and may cause side effects such as liver damage, kidney damage, bone marrow suppression, and lung damage High. On the other hand, 1,5-D-anhydrofructoses and ascopilone have antioxidant activity and also suppress inflammatory cell activation (active oxygen production). It is thought to attenuate the inflammatory tissue damage seen in some antitumor agents. Therefore, when used in combination with other antitumor agents, it can be expected to be applied not only to enhancement of antitumor effects, but also to adjuncts to the treatment of iridaku which leads to reduction of side effects. Disclosure of the invention
- An object of the present invention is to provide 1,5-D-anhydrofluc! It is an object of the present invention to provide the use of mono- and z- or escopilone for inhibiting tumor growth or metastasis.
- Another object of the present invention is to provide an antitumor agent having 1,5-D-anhydrofructose and Z or ascopilone as active ingredients, which is expected to suppress inflammation and has an excellent prognosis. .
- antitumor agent characterized in that it contains 1,5-D-anhydrofructose and Z or ascopirone.
- anti-tumor is a concept including an action of suppressing the growth or metastasis of a tumor.
- Ascopirone in the present invention includes, for example, 1,5-D-anhydrofructose dehydratase derived from 1,5-D-anhydrofructose dehydratase derived from Ascomycetes (Ascomycetes), or 1,5-D —Dehydration of 1,5-D-anhydrofructose by chemical or physical manipulations, such as those produced by treating anhydrofructose under alkaline conditions or by heat treatment. Products can be mentioned. Some structural formulas are shown in Fig. 1 as examples of ascopirone.
- the agent of the present invention can be administered by various methods known per se.
- the dosage, administration site, administration interval, period, etc. are determined according to the patient's age, weight, medical condition or other drugs or treatment. Can be determined in consideration of the case of using together.
- the administration method can be, for example, intravenous, subcutaneous, intraperitoneal, or oral administration by injection or infusion, and is not particularly limited.
- agent of the present invention it is also possible to add the agent of the present invention to food, take the food, and take it into the body.
- the dose varies depending on the administration method, the interval between administrations, the type of tumor, and the severity of the patient.
- the dose per dose is 0.00000001 g Zkg-l, 000 mg / kg for ascopilone, preferably 0.001 gZkg to 500 mgZkg, and 1,5-anhydrofurk] ⁇ 0.001 gZkg to 100,000 mg / kg, preferably 0.01 mgZkg to It can be 1,000 mgZkg.
- this single dose can be administered in several divided doses.
- the form of the agent of the present invention examples include, but are not limited to, tablets, capsules, powders, granules, suppositories, injections, and transdermal absorbents.
- the agent of the present invention may also contain components necessary for preparing the preparation, such as a preparation carrier, an excipient, and a stabilizer. Further, as long as the effects of the present invention are exerted, the composition may contain other antitumor agents, other pharmacological components, or nutritional components such as glucose.
- Adherent cancer cell line C57BL / 6 mouse melanoma cell line (B16 melanoma), human lung adenocarcinoma cell line (A549), human keratinocyte-derived tumor-like cell line (HaCaT), human uterine carcinoma cell lines (H e L a) is 10% FCS ( ⁇ shea calf serum) and DMEM medium supplemented with 2% penicillin Z streptomycin, 37 ° C, and cultured under the conditions of C_ ⁇ 2 concentration of 5%.
- THP-1 pre-myeloid leukemia cell line
- FCS FCS
- RPMI 1640 medium 2% Penicillium phosphorus Bruno streptomycin, 37 ° C, C 0 2 concentration 5% under conditions of And cultured. How to measure the number of live cells
- B16 me1 anoma cells grown on a 6-well plate were fixed with 2% gludealdehyde, stained with 4% crystal violet, and the stainable cells were determined as viable cells. How to measure the percentage of cell death and the percentage of cells in each cell cycle
- the cell culture was stimulated with various concentrations of Ascopyrone P solution (Ascopiron P dissolved in dimethyl sulfoxide (DMSO)), and after culturing for a predetermined time, the cells were collected in a floating state using trypsin. Then, the cells were fixed with 70% ethanol at 4 ° C for 30 minutes, and then stained with 50 gZm1 propidium moxide (PI) solution. Thirty minutes later, DNA histograms were generated using FACS and examined for cell death rates and cell cycles. How to measure the number of adherent cells
- ascopilone P exhibits a cell-killing effect with a wide spectrum, regardless of the type of cancer derived from each cancer cell.
- apoptotic specific DNA fragmentation was observed 48 hours after addition of ascopilone II (1.4 mM) (FIG. 3). From this, it was confirmed that cell death caused by ascopilone P was apoptosis, and the same results were obtained in a system using A549 cells.
- ascopilone P was found to induce cell death within 48 hours at 0.35 mM (FIG. 4).
- HaCa T cells have the characteristics of tumor cells in the presence of 10% FCS, but are known to have characteristics similar to normal cells in the presence of low concentrations of FCS (1% or less). I have. By utilizing this property, the effect of ascopilone P on normal cells was examined. Fig. 5 shows the results. Under the condition of 10% FCS that grows like a tumor, about 30% of cell death was induced within 48 hours after addition of ascopilone P (1.4 mM) (Fig. 5 (c)). In FCS 1% having cell-like characteristics, almost no dead cells were observed even in the presence of 1.4 mM ascopilone P (FIG. 5 (b)). Thus, Ascopilone P is specific for highly proliferative cells (tumor cells) It was suggested that it had no effect on slow-growing cells (normal cells).
- Fig. 7 shows the results. 12.3 mM 1,5-D-anhydrofluc! Reduced cell adhesion by holpol ester to about 25%. Therefore, it was speculated that 1,5-D-anhydrofructose could suppress the function of the integrin molecule, which is considered to play an important role in tumor cell metastasis. The invention's effect
- mice After C 57 BL / 6 mice B 16 me 1 an om a cells (5 X 10 6 cells) were seeded intraperitoneally daily from day 15? 83 (phosphate buffer) and Ascopyrone P solution were intraperitoneally administered (the dose was 20 Omg / kg), and the survival rate was examined (cancer peritonitis model).
- 83 phosphate buffer
- Ascopyrone P solution were intraperitoneally administered (the dose was 20 Omg / kg), and the survival rate was examined (cancer peritonitis model).
- B16me1 anoma cells were inoculated in the abdominal cavity of the mouse beforehand, the individual (mouse) died from the 14th day onward if no administration or PBS was administered.
- the results of examining the life-prolonging effect of ascopirone P on terminal cancer models are shown in FIG.
- the average survival days were 8 days in the aspcopilone P administration group and 4 days in the PBS group, demonstrating anti-tumor effects even in vivo.
- B16me1anoma cells (1 ⁇ 10 5 cells) were subcutaneously seeded on the back of C57BL / 6 mice, and PBS and ascopilone P were applied to the tumor every other day from day 3 to day 13.
- injected subcutaneously into solution dose used in PBS was 2 5mgZkg
- commentary antitumor effect in tumor volume major axis X minor 2 X0. 52
- Fig. 10 No difference was observed between the two days after tumor cell inoculation until day 7, but after day 7, the tumor volume of the aspcopilone P-administered group was significantly smaller than that of the PBS-administered group. I understand.
- THP-1 cells promyelocytic leukemia cells
- Ascopilone P solution Ascopilone P dissolved in DMSO
- Cisplatin solution Similarly dissolved in DMS
- Ascopilone P After stimulating for 48 hours, the cells were thoroughly pipetted and collected in the form of a uniform suspension of single cells. Here, the number of cells was partially measured under a microscope using a hemocytometer. The remaining cell suspension was fixed in 70% ethanol at 4 ° C for 30 minutes, and then stained with a final 5 O ⁇ g / ml propidium moxide (PI) solution.
- PI propidium moxide
- Figure 1 shows an example of the structural formula of ascopirone
- Figure 2 shows the evaluation of aspcopilone P's ability to suppress cell growth by crystal violet staining.
- Figure 3 shows DNA fragmentation analysis by agarose gel electrophoresis.
- Fig. 4 shows quantitative evaluation of dead cells by flow cytometry (FACS).
- Fig. 5 shows quantitative evaluation of dead cells by flow cytometry (FACS).
- Fig. 6 shows cell cycle by flow cytometry (FACS).
- Figure 7 shows the functional evaluation of integrin in leukemia cell lines
- Figure 8 shows (Example 1) the survival rate of mice after administration of ascopilone P
- Figure 9 shows the survival rate of mice after administration of 1,5-D-anhydrofructose (Example 2)
- Fig. 10 (Example 3) Evaluation of tumor volume in mice after administration of aspcopilone P Fig. 11 (Example 4) Evaluation of cell growth inhibitory ability of ascopilone P and cisbratin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/577,447 US7649016B2 (en) | 2003-10-28 | 2004-10-28 | Antitumor medicine |
EP04793334A EP1686122B1 (en) | 2003-10-28 | 2004-10-28 | Antitumor agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003366798 | 2003-10-28 | ||
JP2003-366798 | 2003-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005040147A1 true WO2005040147A1 (ja) | 2005-05-06 |
Family
ID=34510256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016354 WO2005040147A1 (ja) | 2003-10-28 | 2004-10-28 | 抗腫瘍剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7649016B2 (ja) |
EP (1) | EP1686122B1 (ja) |
CN (1) | CN100582101C (ja) |
WO (1) | WO2005040147A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016171165A1 (ja) * | 2015-04-21 | 2016-10-27 | 国立大学法人鹿児島大学 | カスパーゼ1活性化阻害剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080165683A1 (en) * | 2007-01-04 | 2008-07-10 | Debanjan Saha | Method, system, and program product for enhancing network communications between endpoints |
CN102006188B (zh) * | 2010-11-19 | 2014-07-16 | 中兴通讯股份有限公司 | 一种传送网中的路径回切方法及装置 |
EP2885282B1 (en) * | 2012-10-12 | 2017-03-15 | Okinawa Institute of Science and Technology School Corporation | Process for producing dihydro-2h-pyran derivatives |
CN105943945A (zh) * | 2016-06-18 | 2016-09-21 | 冯原 | 一种治疗肺癌的中药组合物、滴丸剂及其制备方法 |
CN108686220A (zh) * | 2018-07-13 | 2018-10-23 | 刘慧荣 | 一种针对甲状腺癌的抗肿瘤剂 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0859646A (ja) * | 1994-08-12 | 1996-03-05 | Ishihara Sangyo Kaisha Ltd | エノピラノース誘導体又はその塩、それらを含有するα−グルコシダーゼ阻害剤 |
JPH09505988A (ja) | 1993-10-15 | 1997-06-17 | ダニスコ エイ/エス | 1,5−D−アンヒドロフルクトース調製のためのα−1,4−グルカンリアーゼの使用 |
WO2000056838A1 (en) | 1999-03-19 | 2000-09-28 | Danisco A/S | Anti-oxidant |
JP2001089377A (ja) | 1999-09-20 | 2001-04-03 | 進 ▲桧▼作 | 1,5−d−アンヒドロフルクトースを含有する細菌増殖の抑制ないし阻止剤 |
WO2001051058A1 (en) | 2000-01-14 | 2001-07-19 | Danisco A/S | Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
WO2001051480A1 (fr) * | 2000-01-13 | 2001-07-19 | Takara Bio Inc. | Agents corrigeant l'erreur de regulation d'expression genique |
WO2002026061A1 (en) | 2000-09-27 | 2002-04-04 | Danisco A/S | Antimicrobial agent |
WO2003038107A2 (en) | 2001-10-31 | 2003-05-08 | Danisco A/S | Process for the production of ascopyrone p |
WO2003038085A1 (en) | 2001-10-31 | 2003-05-08 | Danisco A/S | 1,5-anhydro-d-fructose dehydratase |
WO2003038084A1 (en) | 2001-10-31 | 2003-05-08 | Danisco A/S | Ascopyrone p synthase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9709161D0 (en) * | 1997-05-06 | 1997-06-25 | Danisco | A process of preparing an anti-oxidant |
-
2004
- 2004-10-28 US US10/577,447 patent/US7649016B2/en not_active Expired - Fee Related
- 2004-10-28 EP EP04793334A patent/EP1686122B1/en not_active Not-in-force
- 2004-10-28 CN CN200480031546A patent/CN100582101C/zh not_active Expired - Fee Related
- 2004-10-28 WO PCT/JP2004/016354 patent/WO2005040147A1/ja not_active Application Discontinuation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09505988A (ja) | 1993-10-15 | 1997-06-17 | ダニスコ エイ/エス | 1,5−D−アンヒドロフルクトース調製のためのα−1,4−グルカンリアーゼの使用 |
JPH0859646A (ja) * | 1994-08-12 | 1996-03-05 | Ishihara Sangyo Kaisha Ltd | エノピラノース誘導体又はその塩、それらを含有するα−グルコシダーゼ阻害剤 |
WO2000056838A1 (en) | 1999-03-19 | 2000-09-28 | Danisco A/S | Anti-oxidant |
JP2001089377A (ja) | 1999-09-20 | 2001-04-03 | 進 ▲桧▼作 | 1,5−d−アンヒドロフルクトースを含有する細菌増殖の抑制ないし阻止剤 |
WO2001051480A1 (fr) * | 2000-01-13 | 2001-07-19 | Takara Bio Inc. | Agents corrigeant l'erreur de regulation d'expression genique |
WO2001051058A1 (en) | 2000-01-14 | 2001-07-19 | Danisco A/S | Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
JP2003519660A (ja) | 2000-01-14 | 2003-06-24 | ダニスコ エイ/エス | 耐糖能に影響を与える薬剤を調製するための、環状エーテルの使用 |
WO2002026061A1 (en) | 2000-09-27 | 2002-04-04 | Danisco A/S | Antimicrobial agent |
WO2002026060A1 (en) | 2000-09-27 | 2002-04-04 | Danisco A/S | Antimicrobial agent |
WO2003038107A2 (en) | 2001-10-31 | 2003-05-08 | Danisco A/S | Process for the production of ascopyrone p |
WO2003038085A1 (en) | 2001-10-31 | 2003-05-08 | Danisco A/S | 1,5-anhydro-d-fructose dehydratase |
WO2003038084A1 (en) | 2001-10-31 | 2003-05-08 | Danisco A/S | Ascopyrone p synthase |
Non-Patent Citations (3)
Title |
---|
BRANSOVA ET AL., INT. J. BIOCHEM. CELL BIOL., vol. 27, 1995, pages 701 - 706 |
SHAFIZADEH, F. ET AL., CARBOHYDR. RES., vol. 67, 1978, pages 433 - 447 |
STEVENSON, F. ET AL., CARBOHYDR. RES., vol. 90, 1981, pages 319 - 325 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016171165A1 (ja) * | 2015-04-21 | 2016-10-27 | 国立大学法人鹿児島大学 | カスパーゼ1活性化阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
CN100582101C (zh) | 2010-01-20 |
EP1686122A1 (en) | 2006-08-02 |
EP1686122B1 (en) | 2012-11-21 |
US7649016B2 (en) | 2010-01-19 |
EP1686122A4 (en) | 2009-09-09 |
CN1871227A (zh) | 2006-11-29 |
US20070135517A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4690918A (en) | Use of trichostatin compounds for treating tumor cells | |
CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
Piazza et al. | Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3 | |
KR100424503B1 (ko) | 암전이억제제 | |
WO2016127847A1 (zh) | 绿原酸在制备治疗黑色素瘤的药物中的用途及治疗黑色素瘤的药物 | |
KR20170015507A (ko) | 암을 치료하는 조성물 및 방법 | |
CN105983097B (zh) | 一种抗肿瘤制剂及其制备方法 | |
CN113274485B (zh) | 蝎毒多肽Smp24在制备抗肿瘤药物的应用 | |
WO2005040147A1 (ja) | 抗腫瘍剤 | |
CN106974908B (zh) | 含有hdac抑制剂和ire1抑制剂的药物组合物及用途 | |
CN108236722B (zh) | Idnk抑制剂在制备肝癌治疗药物中的用途 | |
KR102264110B1 (ko) | 신규 바이페닐 유도체 화합물 및 이의 용도 | |
JP4825413B2 (ja) | 抗腫瘍剤 | |
KR20130019341A (ko) | 피불린-3 단백질을 유효성분으로 함유하는 암 줄기세포 성장 억제용 약학적 조성물 | |
CN1823787A (zh) | 灵芝酸在制备癌转移抑制剂中的应用 | |
CN111170980B (zh) | 一种毛蕊异黄酮衍生物及其合成方法和应用 | |
CN110551119B (zh) | 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备和应用 | |
CN103417533A (zh) | Tpca-1作为stat3信号抑制剂在制备抗肿瘤药物中的应用 | |
CN111419832A (zh) | 药物组合物及其在制备***药物中的用途 | |
WO2020168741A1 (zh) | 卡格列净在制备抗肿瘤药物中的应用 | |
JP5439671B2 (ja) | 抗がん剤 | |
Attar et al. | Multifunctional role of Nobiletin in cancer chemoprevention: Multifunctional role of Nobiletin in cancer chemoprevention | |
CN103933044A (zh) | 一种***的药物组合物及用途 | |
CN106540247B (zh) | 肿瘤通用型成纤维细胞疫苗及其制备方法和用途 | |
JP4825957B2 (ja) | 抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480031546.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007135517 Country of ref document: US Ref document number: 10577447 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004793334 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004793334 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10577447 Country of ref document: US |